The anticancer effect of EVO in human colon cancer has also been demonstrated, an effect that is partly attributed to its downregulation of Hypoxia-inducible factor 1-alpha (HIF-1α) in cancer cells through inhibition of IGF-1/PI3K/Akt signaling (Huang et al., 2015). Here, HIF1A is linked to colonic neoplasm.